X2M's $250M AI Data Centre Deal Tops HotCopper Week 35
Brightstar's gold hits and Liontown's lithium debate follow X2M's $250M AI data centre deal in HotCopper's Week 35 wrap; investors ask if its pipeline converts.
Alpha Score of 55 reflects moderate overall profile with moderate value, moderate quality, moderate sentiment. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
X2M Connect signed a binding agreement for its first AI-enabled data centre project, valued at more than $250 million, according to HotCopper's Week 35 wrap of Australia's largest stock forum. The deal topped the most-watched list, ahead of gold explorer Brightstar and diagnostics group AnteoTech. AI, gold, lithium and biotech names dominated the boards across the week.
The agreement follows the creation of a dedicated data centre subsidiary earlier in the week. HotCopper said the big question on the boards is whether X2M can now convert its broader data centre pipeline into actual projects.
Gold explorer Brightstar (ASX: BTR) drew the heaviest discussion among the commodity names after what HotCopper called a monster week on the exploration front. Drilling at Two Mile Hill produced broad, high-grade gold results. The latest results sent the discussion into overdrive, HotCopper said; investors are debating the scale of the mineralised system and what further drilling could add to the company's broader gold story. The gold profile tracks the metal's price drivers.
Liontown (ASX: LTR) led the most-discussed names and stayed one of the hottest lithium names on the boards. HotCopper said investors are dissecting the latest Kathleen Valley performance and what FY27 could look like while the operation ramps up. The improving lithium backdrop, HotCopper said, is fuelling debate over the recent rally's durability and what it means for Liontown's valuation. Broader commodities analysis covers the supply and demand data behind that backdrop.
AnteoTech (ASX: ADO) was also among the most-watched names after reporting that leads generated at a major diagnostics conference significantly expanded its Life Sciences sales pipeline. The update comes shortly after a strategic deal with South Korea's Xerabrid. Investors are now focused on whether the partnerships and new leads translate into commercial orders and revenue, HotCopper said.
The technology debate extended to BrainChip (ASX: BRN), whose latest developments include the new Akida integration with IBM's Symphony Community Edition. HotCopper said investors keep asking when the technology translates into meaningful commercial revenue.
Mesoblast (ASX: MSB) rounded out the most-discussed list after its FY26 results and operational update, with Ryoncil now firmly at the centre of the investment story, HotCopper said.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.